Although the COVID-19 pandemic will have a negative impact on procedure volumes and market growth in 2020, the Asia Pacific IC device market will continue to grow rapidly, driven by the increasing prevalence and diagnosis of CAD among the patient population. Rising uptake of next-generation DES and BRS later in the forecast period, increasing PCI volumes, and the recent increase of the price ceiling for coronary stents in the large Indian market will all contribute to overall expansion through 2029.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for IC devices in Asia Pacific across a 10-year period.
The Asia Pacific IC device market will be impacted by the COVID-19 pandemic in the early years of the forecast.
What guidance or recommendations have been issued for IC procedures in the face of infection containment and self isolation measures?
How will the pandemic impact clinical trials and product launches?
The continued launch of newer BRS and DCBs will drive a shift in device preference in procedures that have traditionally been performed with DES or BMS, respectively.
How are current recommendations for use dictating adoption of DES, BMS, and BRS for CAD patients?
What is the evolving role of DCBs in PCIs in the current clinical landscape?
What has been impact of the launch of Abbott Laboratories' XIENCE Sierra on the DES market?
Price competition will limit revenue growth potential, especially in light of increased cost consciousness among health care facilities.
How will ASP trends vary by country?
What are the effects of government-driven pricing pressure on ASPs, and which product segments will be most impacted?
Which segments will experience the most price competition?
The Asia Pacific IC device market is characterized by the presence of several domestic manufacturers.
What companies lead the different IC device segments?
In which segments are domestic manufacturers challenging the positions of the international manufacturers, and how?
What strategies are used by international competitors to succeed in this market?
What is the role of distributors in the success of international companies?
What strategies can new competitors employ to gain entry into the Asia Pacific coronary stent market?
- Interventional Cardiology Devices - Market Insights - Asia Pacific
Author(s): Sangeetha Iyer, Pharm.D
Sangeetha Iyer is an analyst within the Cardiovascular Medtech Insights team at Decision Resource Group, specializing in structural heart closure and vascular access device markerts across the Asia Pacific region, as well as medical device pricing and regulations in China and Japan. Sangeetha has represnted India at the European Society of Cardiology confrerence in Greece(2016) and Sweden(2017), where her research poster was awarded the top prize. Sangeetha holds a Doctor of Pharmacy degree from the Manipal Academy of Higher Education. Follow Sangeetha on twitter: @Slyer_DRG